Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis C

|Only 20% of patients with chronic hepatitis C (CHC) progress to cirrhosis [1]. Progressive fibrosis is the hallmark of an unfavorable course and is related to several factors such as male gender, contracting the disease at an older age, features of the metabolic syndrome, iron overload, ethanol abuse, and co-infection with hepatitis B or human acquired immunodeficiency viruses. However, the course of the disease is highly variable from individual to individual. Liver biopsy remains the gold standard for evaluating necroinflammation (grade) and fibrosis (stage) in CHC [2]; however, this pre-eminence is currently being examined due to its intrinsic risks and limitations. Liver biopsy is an invasive procedure that carries a risk of complications, although rarely severe. The biopsy provides a very small specimen of liver tissue and has both a significant rate of sampling error, especially when the cylinder obtained is less than 25 mm in length, and interobserver variability. The risk-benefit ratio of liver biopsy is insufficient to maintain it as a firstline procedure, and new and non-invasive criteria for the evaluation of liver fibrosis are urgently needed [3]. A discussion on the molecular pathobiology of liver fibrogenesis is beyond the scope of this article (for a review see references [4] and [5]. The ideal marker for liver fibrosis must be specific to fibrosis of the liver, not influenced by co-morbidities, sensitive, reproducible, and informative for both the current stage of fibrosis as well as the rate of fibrogenesis activity [6]. For practical purposes, non-invasive fibrosis markers can be classified as direct (Class I biomarkers), indirect (Class II biomarkers), and imaging methods [7].

• Publication year

  2011

• Venue

  Hepatitis Monthly

• Publication date

  2011-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5812/kowsar.1735143X.738PMID 22235211PMCID 3234540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

  2011cited by this paper
• New Approaches for Biomarker Discovery: The Search for Liver Fibrosis Markers in Hepatitis C Patients

  2011cited by this paper
• A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis

  2010cited by this paper
• Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: A comparative analysis of nine scoring methods

  2010cited by this paper
• Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

  2010cited by this paper
• Circulating markers of liver fibrosis progression.

  2010influential reference
• Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI

  2010cited by this paper
• Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey.

  2009cited by this paper
• Systematic review: non‐invasive methods of fibrosis analysis in chronic hepatitis C

  2009cited by this paper
• Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications

  2007cited by this paper
• Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

  2006cited by this paper
• Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging.

  2006cited by this paper
• Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.

  2005influential reference
• The liver biopsy in chronic hepatitis C: a view from the other side of the microscope.

  2005influential reference
• Serum markers detect the presence of liver fibrosis: a cohort study.

  2004cited by this paper
• Natural history of chronic hepatitis C

  2002cited by this paper
• Serum hyaluronan as a marker of liver fibrosis.

  1995cited by this paper

• Glaucocalyxin A attenuates carbon tetrachloride‐induced liver fibrosis and improves the associated gut microbiota imbalance

  2023cites this paper
• Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma

  2023cites this paper
• Nicorandil reduces morphine withdrawal symptoms, potentiates morphine antinociception, and ameliorates liver fibrosis in rats.

  2023cites this paper
• Liver sinusoidal endothelial S1pr2 regulates experimental liver fibrosis through YAP/TGF‐β signaling pathway

  2023cites this paper
• PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction

  2023cites this paper
• Nicorandil/ morphine crosstalk accounts for antinociception and hepatoprotection in hepatic fibrosis in rats: Distinct roles of opioid/cGMP and NO/KATP pathways.

  2023cites this paper
• Research progress of metformin in the treatment of liver fibrosis.

  2023cites this paper
• Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment

  2023cites this paper
• LncRNA-MIAT activates hepatic stellate cells via regulating Hippo pathway and epithelial-to-mesenchymal transition

  2023cites this paper
• Mori fructus aqueous extracts attenuates liver injury by inhibiting ferroptosis via the Nrf2 pathway

  2023cites this paper
• Hematological Abnormalities in Cirrhosis: A Narrative Review

  2023cites this paper
• DNMT3a-mediated methylation of TCF21/hnRNPA1 aggravates hepatic fibrosis by regulating the NF-κB signaling pathway.

  2023cites this paper
• Activated Hepatic Stellate Cells (Ito Cells) - Marker of Advanced Fibrosis in Chronic Viral Hepatitis C: A Pilot Study.

  2023cites this paper
• Protective Effects of Phytic Acid on CCl4-Induced Liver Fibrosis in Mice

  2023cites this paper
• Dietary oxidized frying oil activates hepatic stellate cells and accelerates the severity of carbon tetrachloride- and thioacetamide-induced liver fibrosis in mice.

  2023cites this paper
• Iron as a therapeutic target in chronic liver disease

  2023cites this paper
• Generation of multilineage liver organoids with luminal vasculature and bile ducts from human pluripotent stem cells via modulation of Notch signaling

  2023cites this paper
• Sulodexide attenuates liver fibrosis in mice by restoration of differentiated liver sinusoidal endothelial cell.

  2023cites this paper
• Peptide-Based siRNA Nanocomplexes Targeting Hepatic Stellate Cells

  2023cites this paper
• FAT10 Silencing Prevents Liver Fibrosis through Regulating SIRT1 Expression in Hepatic Stellate Cells

  2023cites this paper
• Microfat exerts an anti-fibrotic effect on human hypertrophic scar via fetuin-A/ETV4 axis

  2023cites this paper
• Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis

  2023cites this paper
• The endoplasmic reticulum stress sensor IRE1 regulates collagen secretion through the enforcement of the proteostasis factor P4HB/PDIA1 contributing to liver damage and fibrosis

  2023cites this paper
• Induced pluripotent stem cell-based therapies for organ fibrosis

  2023cites this paper
• Multi‐omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures

  2023cites this paper
• Chromatographic Scalable Method to Isolate Engineered Extracellular Vesicles Derived from Mesenchymal Stem Cells for the Treatment of Liver Fibrosis in Mice

  2023cites this paper
• A Hierarchical Siamese Network for Noninvasive Staging of Liver Fibrosis Based on US Image Pairs of the Liver and Spleen

  2023cites this paper
• CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis

  2023cites this paper
• Fibroblasts—Warriors at the Intersection of Wound Healing and Disrepair

  2023cites this paper
• Fibroblasts in liver cancer: functions and therapeutic translation.

  2023cites this paper
• The Resolvin D2-GPR18 Axis Enhances Bone Marrow Function and Limits Hepatic Fibrosis in Aging

  2023cites this paper
• Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD

  2023cites this paper
• The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation

  2023cites this paper
• Regulatory Functions and Mechanisms of Circular RNAs in Hepatic Stellate Cell Activation and Liver Fibrosis

  2023cites this paper
• Albumin-Based Silibinin Nanocrystals Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy.

  2023cites this paper
• Deleterious liver-adipose crosstalk in obesity: Hydroethanolic extract of Lampaya medicinalis Phil. (Verbenaceae) counteracts fatty acid-induced fibrotic marker expression in human hepatocytes.

  2023cites this paper
• Protective role of resveratrol against VCM-induced hepatotoxicity in male wistar rats

  2023cites this paper
• Regulatory T cells (Tregs) in liver fibrosis

  2023cites this paper
• Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients

  2023cites this paper
• Liver fibrosis-4 score predicts outcome of patients with ischemic stroke undergoing intravenous thrombolysis

  2023cites this paper
• Prolyl isomerase Pin1 promotes extracellular matrix production in hepatic stellate cells through regulating formation of the Smad3-TAZ complex.

  2023cites this paper
• Hepatocyte-Specific Triggering of Hepatic Stellate Cell Profibrotic Activation by Apoptotic Bodies: The Role of Hepatoma-Derived Growth Factor, HIV, and Ethanol

  2023cites this paper
• PTEN‐AKT pathway attenuates apoptosis and adverse remodeling in ponatinib‐induced skeletal muscle toxicity following BMP‐7 treatment

  2023cites this paper
• Predicting Post-hepatectomy Liver Failure Preoperatively for Child-Pugh A5 Hepatocellular Carcinoma Patients by Liver Stiffness

  2023cites this paper
• Mulberroside A ameliorates CCl4‐induced liver fibrosis in mice via inhibiting pro‐inflammatory response

  2023cites this paper
• Downregulation of KIAA1199 alleviated the activation, proliferation, and migration of hepatic stellate cells by the inhibition of epithelial–mesenchymal transition

  2023cites this paper
• Oroxylin A activates ferritinophagy to induce hepatic stellate cell senescence against hepatic fibrosis by regulating cGAS-STING pathway.

  2023cites this paper
• The Values and Perspectives of Organoids in the Field of Metabolic Syndrome

  2023cites this paper
• Inverse projection of axisymmetric orientation distributions

  2023cites this paper
• Ferroptosis as an emerging therapeutic target in liver diseases

  2023cites this paper
• Schizandrin C regulates lipid metabolism and inflammation in liver fibrosis by NF-κB and p38/ERK MAPK signaling pathways

  2023cites this paper
• Phillygenin Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis: Suppression of Inflammation and Wnt/β-Catenin Signaling Pathway

  2023cites this paper
• Effects of Nelumbo nucifera Gaertn. Petal Tea Extract on Hepatotoxicity and Oxidative Stress Induced by Mancozeb in Rat Model

  2023cites this paper
• An updated review of a novel method for examining P53 mutations in different forms of cancer.

  2023cites this paper
• Impact of Gut Microbiota on Liver Transplantation.

  2023cites this paper
• MicroRNA-29a-3p prevents Schistosoma japonicum-induced liver fibrosis by targeting Roundabout homolog 1 in hepatic stellate cells

  2023cites this paper
• Mammalian cleavage factor 25 targets KLF14 to inhibit hepatic stellate cell activation and liver fibrosis.

  2023cites this paper
• Aqueous extract of Amydrium sinense (Engl.) H. Li alleviates hepatic fibrosis by suppressing hepatic stellate cell activation through inhibiting Stat3 signaling

  2023cites this paper
• Targeted Deletion of Thymosin Beta 4 in Hepatic Stellate Cells Ameliorates Liver Fibrosis in a Transgenic Mouse Model

  2023cites this paper
• Artifacts in two-dimensional shear wave elastography of liver

  2023cites this paper
• N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment

  2023cites this paper
• Lp-PLA2 silencing ameliorates inflammation and autophagy in nonalcoholic steatohepatitis through inhibiting the JAK2/STAT3 pathway

  2023cites this paper
• Roxarsone inhibits hepatic stellate cell activation and ameliorates liver fibrosis by blocking TGF-β1/Smad signaling pathway.

  2023cites this paper
• Demonstrating HOCl as a potential biomarker for liver fibrosis using a highly sensitive fluorescent probe

  2023cites this paper
• Ganoderma lucidum: Current advancements of characteristic components and experimental progress in anti-liver fibrosis

  2023cites this paper
• Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis

  2023cites this paper
• Regulators, functions, and mechanotransduction pathways of matrix stiffness in hepatic disease

  2023cites this paper
• Imatinib suppresses activation of hepatic stellate cells by targeting STAT3/IL‐6 pathway through miR‐124

  2023cites this paper
• Pre‐clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis

  2023cites this paper
• Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study

  2023cites this paper
• Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism

  2023cites this paper
• Spatiotemporal Dynamics of Vcam1 Regulates Cholangiocarcinoma Mass Expansion and Tumor Dissemination under Growth-suppressive Peritumoral Myofibroblasts

  2023cites this paper
• The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells

  2023cites this paper
• Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug

  2023cites this paper
• Metabolic Hijacking of Hexose Metabolism to Ascorbate Synthesis Is the Unifying Biochemical Basis of Murine Liver Fibrosis

  2023cites this paper
• Gut Lactobacillus and Probiotics Lactobacillus lactis/rhamnosis Ameliorate Liver Fibrosis in Prevention and Treatment

  2023cites this paper
• QSM Throughout the Body

  2023cites this paper
• Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review

  2023cites this paper
• Relationship between the Mediterranean diet and risk of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A cross-sectional analysis of the RaNCD cohort

  2023cites this paper
• Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment

  2023cites this paper
• Spatiotemporal regulation of cholangiocarcinoma growth and dissemination by peritumoral myofibroblasts in a Vcam1-dependent manner

  2023cites this paper
• GL-V9 ameliorates liver fibrosis by inhibiting TGF-β/smad pathway.

  2023cites this paper
• Hypoxia-inducible factor-1α-mediated SERPINE-1 expression in ischemic urinary bladder

  2023cites this paper
• The Role of Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitors in The Attenuation of CCl4-Induced Liver Fibrosis in Rats

  2023cites this paper
• BRD4 promotes hepatic stellate cells activation and hepatic fibrosis via mediating P300/H3K27ac/PLK1 axis.

  2023cites this paper
• Liver Assessment in Patients with Ataxia-Telangiectasia: Transient Elastography Detects Early Stages of Steatosis and Fibrosis

  2023cites this paper
• The Expanding Phenotype of ZTTK Syndrome Due to the Heterozygous Variant of SON Gene Focusing on Liver Involvement: Patient Report and Literature Review

  2023cites this paper
• Exosomes in liver fibrosis: The role of modulating hepatic stellate cells and immune cells, and prospects for clinical applications

  2023influential citation
• Damaged collagen detected by collagen hybridizing peptide as efficient diagnosis marker for early hepatic fibrosis.

  2023cites this paper
• Arginine vasopressin deficiency and conivaptan (a V1a–V2 receptor antagonist) treatment reverses liver damage and fibrosis in rats with chronic portocaval anastomosis

  2023cites this paper
• Design, synthesis and anti-hepatic fibrosis activity of novel diphenyl vitamin D receptor agonists.

  2023cites this paper
• Green tea actions on miRNAs expression - An update.

  2023cites this paper
• Schisandrin B promotes senescence of activated hepatic stellate cell via NCOA4-mediated ferritinophagy

  2023cites this paper
• Gandouling inhibits hepatic fibrosis in Wilson's disease through Wnt-1/β-catenin signaling pathway.

  2023cites this paper
• Therapeutic Effect of Prolyl Endopeptidase Inhibitor in High-fat Diet-induced Metabolic Dysfunction-associated Fatty Liver Disease

  2023cites this paper
• Liver-Spleen Volume Ratio as a Predictor of Native Liver Survival in Patients with Biliary Atresia.

  2023cites this paper
• A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation

  2023cites this paper
• The SLIT/ROBO Pathway in Liver Fibrosis and Cancer

  2023cites this paper
• Delivery of hydroxycamptothecin via sonoporation: An effective therapy for liver fibrosis.

  2023cites this paper
• Transcriptional regulation of Glis2 in hepatic fibrosis

  2023cites this paper